Skip to main content

Table 1 Characteristics of patients on SABA over-use, on PRT with high OCS exposure, and on PRT

From: High oral corticosteroid exposure and overuse of short-acting beta-2-agonists were associated with insufficient prescribing of controller medication: a nationwide electronic prescribing and dispensing database analysis

  SABA over-use (23.9 per 100,000) PRT with high OCS exposure (101.2 per 100,000) PRT (4786.5 per 100,000)
Sex (%) 95% CI
 Female 29.5 18.2–44.2 50.0 42.9–57.1 55.9 54.9–56.9
 Male 70.5 55.8–81.8 50.0 42.9–57.1 44.1 43.1–45.1
Age, med P25–P75 61.0 50.8–73.5 69.0 57.3–78.8 64.0 47.0–76.0
Age (%) 95% CI
 15:44 11.4 5.0–24.0 8.1 4.9–12.9 28.8 27.9–29.8
 45:64 45.5 31.7–59.9 30.1 24.0–37.0 21.8 20.9–22.6
 > 64 43.2 29.7–57.8 61.8 54.7–68.5 49.4 48.3–50.4
Maintenance-to-total prescribed (%) 95% CI
 No controller prescribed 15.9 7.9–29.4   
 > 0 to 20% 25.0 14.6–39.4 2.7 1.2–6.1 0.3 0.2–0.4
 ≥ 20 to < 50% 31.8 20.0–46.6 35.5 29.0–42.6 3.3 2.9–3.7
 ≥ 50 to < 70% 20.5 11.1–34.5 28.5 22.5–35.4 8.2 7.6–8.8
 ≥ 70 to < 90% 6.8 2.3–18.2 28.0 22.0–34.8 16.3 15.5–17.1
 ≥ 90 to 100% 0.0 0.0–8.0 5.4 2.9–9.6 72.0 71.0–72.9
Primary adherence to controller medication (%) 95% CI
 0% 10.8 4.3–24.7 3.8 1.8–7.6 6.9 6.4–7.4
 > 0 to 20% 5.4 1.5–1.8 5.4 2.9–9.6 5.2 4.8–5.7
 > 20 to 50% 13.5 5.9–27.9 31.7 25.4–38.7 28.2 27.3–29.1
 > 50 to 70% 13.5 5.9–27.9 23.1 17.6–29.7 18.1 17.2–18.9
 > 70 to 90% 35.1 21.8–51.2 21.0 15.7–27.4 19.4 18.6–20.2
 > 90 to 100% 21.6 11.4–37.2 15.1 10.6–20.9 22.3 21.4–23.1
  1. PRT persistent respiratory treatment, SABA short-acting beta2 agonist, OCS oral corticosteroids